DSM and Chemtrix Sign Collaboration Agreement
News Feb 22, 2013
DSM Pharmaceutical Products has announced that it has signed a collaboration agreement with Chemtrix B.V., The Netherlands, in the field of Continuous Flow Chemistry to provide sustainable equipment and, development and manufacturing services to the pharmaceutical industry.
The agreement brings together the expertise of both parties in continuous flow chemistry to better serve the pharmaceutical industry with processes for the development and manufacture of active pharmaceutical ingredients (APIs), which require new technologies to increase sustainability, reduce energy consumption and provide benefits for cost-of-goods.
Chemtrix’ specializes in ready-to-use laboratory and kilo-scale micro reactors, as well as reactor and process design for industrial reactors, which complement DSM’s proven track record in drug synthesis route development, scale-up and implementation of continuous flow processes for manufacturing.
DSM achieved one of the first industrial scale, FDA approved uses of micro reactors for making a pharmaceutical at commercial scale under current Good Manufacturing Practices (cGMP) at their facility in Linz, Austria.
Initially the DSM-Chemtrix collaboration will offer an Industrial Flow Process Development package to clients, in order to provide tailor-made, scalable flow chemistry solutions.
This package covers all phases of process design, from scanning chemistries, chemistry development, route scouting, equipment design and scale-up for fully continuous or integrated processes.
Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "Working with Chemtrix underlines the further advancement of DSM's stated strategy toward strategic partnerships to excel in providing new customer solutions. DSM is a global leader in cGMP continuous flow chemistry manufacturing, with a commitment to the future of pharmaceutical manufacturing in a sustainable manner."
Simon Hickling Ph.D., Senior Business Manager at DSM, added, “Continuous flow chemistries are becoming more important in API manufacturing, as the pharmaceutical industry focuses on sustainable manufacturing solutions and competitive cost-of-goods. Together with Chemtrix we now offer a complete turnkey solution to manufacturing in flow-reactors from conception to cGMP bulk manufacturing; flow chemistry to the power of two.”
Hugo Delissen, CEO of Chemtrix BV, stated, “Together with DSM we are the most complete flow chemistry partner for pharmaceutical and fine chemical companies. Delivering a complete package of equipment and services based on our joint knowledge ranging from lab (milligrams) to production (ton) scale, ensures the delivery of the best possible solutions for our joint customers.”
“With this collaboration we complete our product portfolio which has always been based on scalability. Using micro reactors for flow chemistry method development is only valuable if customers can use it to produce their products on commercial scale. To ensure that the whole scale-up process will run smoothly together we offer a complete service package which will help our customers to implement this process intensification technology to improve the sustainability and safety of their processes.”, added Dr. Charlotte Wiles, Chief Technology Officer of Chemtrix BV.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE